Abstract
Objective:
This study aimed to compare the systemic bioavailability of two aciclovir tablets, Rouz-Aciclovir (test) and Zovirax® (reference), in 12 healthy volunteers.
Methods:
In a crossover design, each subject received a single oral dose of aciclovir 400 mg followed by a 7-day washout period. Plasma concentrations of aciclovir were measured for up to 12 hours using a validated high-performance liquid chromatography method with a lower limit of quantification of 50 μg/L.
Results:
The mean values of maximum plasma concentration (Cmax), time to Cmax (tmax), area under the plasma concentration-time curve from time 0 to 12 hours (AUC12) and from time 0 to infinity (AUC∞), and plasma half-life following administration of the test product were 999.6 μg/L, 2.08 h, 4911.2 μg/L · h, 5417.7 μg/L · h and 3.08 h, respectively, and for the reference product 775.8 μg/ L, 2.58 h, 3862.1 μg/L · h, 4295.4 μg/L · h and 3.14 h, respectively. The test/ reference geometric ratio for Cmax (90% CI) was 1.30 (97.1, 174.8). The test/ reference geometric ratios for AUC12 (90% CI) and AUC∞ (90% CI) were 1.26 (99.7, 159.1) and 1.24 (98.9, 155.6), respectively. Therefore, the 90% CIs of Cmax, AUC12 and AUC∞ were not within the acceptable range of 80 and 125 suggested by the US FDA bioequivalence guideline.
Conclusion:
The results of the present study suggest that the aciclovir test product was not bioequivalent to the reference product. The exact reasons for this remain to be determined. However, we think the difference should be attributed to the difference in the type and amounts of ingredients used in the formulation that probably affect the contact time of aciclovir with the sites of absorption in the gut.
Similar content being viewed by others
Notes
The use of trade names is for product identification purposes only and does not imply endorsement.
References
Elion GB, Furman PA, Fyfe JA, et al. The selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci USA 1977; 74: 5716–20
DeClercq E. Antivirals for the treatment of herpesvirus infections. J Antimicrob Chemother 1993; 32Suppl. A: 121–32
McEvoy G. AHFS Drugs information, American Society of Health System Pharmacists. Bethesda (MD): Atlantic Books, 1998: 471–80
Fletcher C, Bean B.Evaluation of oral acyclovir therapy. Drug Intell Clin Pharm 1985; 19: 518–24
Wagstaff AJ, Faulds D, Goa KL. Acyclovir: a reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994; 47: 153–205
Bahrami G, Mirzaeei S, Kiani A. Determination of acyclovir in human serum by high-performance liquid chromatography using liquid-liquid extraction and its application in pharmacokinetic studies. J Chromatogr B 2005; 816: 327–31
Bangaru RA, Bansal YK, Rao ARM, et al. Rapid, simple and sensitive high-performance liquid Chromatographic method for detection and determination of acyclovir in human plasma and its use in bioavailability studies. J Chromatogr B 2000; 739: 231–7
Vergin H, Kikuta C, Mascher H, et al. Pharmacokinetics and bioavailability of different formulations of acyclovir. Arzneimittelforschung 1995; 45: 508–15
Najib NM, Idkaidek N, Beshtawi M, et al. Bioequivalence assessment of Lovrak (Julphar, UAE) compared with Zovirax (GlaxoWellcome, UK), two brands of acyclovir, in healthy human volunteers. Biopharma Drug Dispos 2005; 26: 7–12
Meadows KC, Dressman JB. Mechanism of acyclovir uptake in rat jejunum. Pharm Res 1990; 7: 299–303
Miserocchi E, Modorati G, Galli L, et al. Efficacy of valacyclovir vs acyclovir for the prevention of recurrent herpes simplex virus eye disease: a pilot study. Am J Ophthalmol 2007; 144: 547–51
Ghosh PK, Majithiya RJ, Umrethia ML, et al. Design and development of microemulsion drug delivery system of acyclovir for improvement of oral bioavailability. AAPS Pharm Sci Tech 2006; 7article 77): E1–6
Corti G, Maestrelli F, Cirri M, et al. Development and evaluation of an in vitro method for prediction of human drug absorption: II. Demonstration of the method suitability. Eur J Pharm Sci 2006; 27: 354–62
Lindenberg M, Kopp S, Dressman JB. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the Biopharmaceutics Classification System. Eur J Pharm Biopharm 2004; 58: 265–78
Blume HH, Schug BS. The Biopharmaceutics Classification System (BCS): class III drugs. Better candidate for BA/BE waiver? J Pharm Sci 1999; 9: 117–21
Polli JE. In vitro-in vivo relationships of several ‘immediate’ release tablets containing a low permeability drug. Adv Exp Med Biol 1997; 423: 191–8
Koch KM, Parr AF, Tomlinson JJ, et al. Effect of sodium acid pyrophosphate on ranitidine bioavailability and gastrointestinal transit time. Pharm Res 1993; 10: 1027–30
Adkin DA, Davis SS, Sparrow RA, et al. The effect of mannitol on the oral bioavailability of cimetidine. J Pharm Sci 1995; 84: 1405–9
Acknowledgements
This study was funded by Rouzdaru Pharmaceutical Co. Ltd, Tehran, Iran. Dr Ghaffari is an employee of Rouzdaru Pharmaceutical Co. Ltd. The other authors have no conflicts of interest that are directly relevant to the content of this study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Amini, H., Javan, M., Gazerani, P. et al. Lack of Bioequivalence between Two Aciclovir Tablets in Healthy Subjects. Clin. Drug Investig. 28, 47–53 (2008). https://doi.org/10.2165/00044011-200828010-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00044011-200828010-00006